![](/_next/image?url=%2Fwp-content%2Fuploads%2F2024%2F08%2FNews-Eurofins_Preview-news-sito.png&w=3840&q=85)
CellPly announces acceptance of one abstract at the CICON23 conference
CellPly announces acceptance of one abstract at the CICON23 conference
Conference: Translating Science into Survival
CellPly, the pioneer in multiparametric single-cell analysis and automated potency testing for cell therapy, today announced that it will present data in a poster presentation at the Seventh International Cancer Immunotherapy Conference: Translating Science into Survival, being held in Milan, Italy, on Sep. 20-23, 2023.
The data reported in this abstract, generated within a scientific collaboration with the team of Dr. Richard Harbottle at the DKFZ institute, Heidelberg, Germany, show the characterization of TCR-T cells engineered from Dr. Harbottle’s team through the VivaCyte® technology for the analysis of cell function at the single-cell resolution developed at Cellply. Thanks to a novel single-cell serial killing assay, researchers were able to demonstrate that T cells engineered with a non-viral DNA nanovector acquire the capacity to exert their cytotoxic function multiple times before their exhaustion, leading to an increase in T cell potency.
Abstract number: P528
Session: POSTER SESSION A – EVEN NUMBERS Thursday, Sept. 21
![](/_next/image?url=%2Fwp-content%2Fuploads%2F2023%2F12%2FCICON23.jpg&w=3840&q=85)